Skip to main content
SpringerLink
Log in
Book cover

Oncoimmunology pp 311–319Cite as

Tumor-Targeted Antibodies

  • Chapter
  • First Online:

  • 2950 Accesses

Abstract

At the end of the nineteenth century in 1894, Dr. Pierre-Paul Emile Roux from the Pasteur Institute in Paris demonstrated the clinical efficacy of serotherapy to treat diphtheria. A century later in 1994, Prof. Ronald Levy from Stanford University, CA, USA, demonstrated that antibodies could also be used to treat cancers. Since then, major improvements have been made in the design and production of antibodies, and they are now part of the conventional therapies of many cancers. More recently, it has been shown that antibodies could also be used to generate adaptive antitumor immunity in patients with cancer, by targeting co-inhibitory receptors expressed at the surface of T cells. The promising results obtained with such immunomodulatory antibodies open many perspectives for synergistic combinatorial strategies between tumor-targeted and immune-targeted antibodies.

This is a preview of subscription content, log in via an institution.

References

  1. Roux E, Martin L, Chaillou A. Trois cents cas de diphtérie traités par le sérum antidiphtérique. Ann Inst Pasteur. 1894;8:640–61.

    Google Scholar 

  2. Miller RA, Maloney DG, Warnke R, Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. New Engl J Med. 1982;306:517–22.

    Article  CAS  PubMed  Google Scholar 

  3. Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 1994;84:2457–66.

    CAS  PubMed  Google Scholar 

  4. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84:548–58.

    Article  CAS  PubMed  Google Scholar 

  5. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495–7.

    Article  PubMed  Google Scholar 

  6. Liu JKH. The history of monoclonal antibody development—progress, remaining challenges and future innovations. Ann Med Surg. 2014;3:113–6.

    Article  Google Scholar 

  7. Vacchelli E, Pol J, Bloy N, Eggermont A, Cremer I, Fridman WH, et al. Trial watch: tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology. 2015;4:e985940.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363:1324–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Houot R, Kohrt HE, Marabelle A, Levy R. Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy. Trends Immunol. 2011;32:510–6.

    Article  CAS  PubMed  Google Scholar 

  10. Weng W-K, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 2003;21:3940–7.

    Article  CAS  PubMed  Google Scholar 

  11. Cheung N-K V, Sowers R, Vickers AJ, Cheung IY, Kushner BH, Gorlick R. FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor. J Clin Oncol. 2006;24:2885–90.

    Article  PubMed  Google Scholar 

  12. Schneider-Merck T, van Bueren JJL, Berger S, Rossen K, van Berkel PHC, Derer S, et al. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J Immunol. 2010;184:512–20.

    Article  CAS  PubMed  Google Scholar 

  13. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov. 2009;8:226–34.

    Article  CAS  PubMed  Google Scholar 

  14. Olive D, le Thi S, Xerri L, Hirsch I, Nunès JA. The role of co-inhibitory signals driven by CTLA-4 in immune system. Med Sci. 2011;27:842–9.

    Google Scholar 

  15. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science. 2008;322:271–5.

    Article  CAS  PubMed  Google Scholar 

  16. Ghiotto M, Gauthier L, Serriari N, Pastor S, Truneh A, Nunès JA, et al. PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1. Int Immunol. 2010;22:651–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Boyerinas B, Jochems C, Fantini M, Heery CR, Gulley JL, Tsang KY, et al. Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res. 2015;3:1148–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Topp MS, Kufer P, Gökbuget N, Goebeler M, Klinger M, Neumann S, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29:2493–8.

    Article  CAS  PubMed  Google Scholar 

  19. Topp MS, Gokbuget N, Zugmaier G, Klappers P, Stelljes M, Neumann S, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014;32:4134–40.

    Article  CAS  PubMed  Google Scholar 

  20. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008;321:974–7.

    Article  CAS  PubMed  Google Scholar 

  21. Bacac M, Fauti T, Sam J, Colombetti S, Weinzierl T, Ouaret D, et al. A novel carcinoembryonic antigen T-cell bispecific antibody (CEA TCB) for the treatment of solid tumors. Clin Cancer Res. 2016;22:3286–97.

    Article  CAS  PubMed  Google Scholar 

  22. Han H, Ma J, Zhang K, Li W, Liu C, Zhang Y, et al. Bispecific anti-CD3 x anti-HER2 antibody mediates T cell cytolytic activity to HER2-positive colorectal cancer in vitro and in vivo. Int J Oncol. 2014;45:2446–54.

    Article  CAS  PubMed  Google Scholar 

  23. Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov. 2012;11:215–33.

    Article  CAS  PubMed  Google Scholar 

  24. Ma Y, Conforti R, Aymeric L, Locher C, Kepp O, Kroemer G, et al. How to improve the immunogenicity of chemotherapy and radiotherapy. Cancer Metastasis Rev. 2011;30:71–82.

    Article  CAS  PubMed  Google Scholar 

  25. Stagg J, Loi S, Divisekera U, Ngiow SF, Duret H, Yagita H, et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A. 2011;108:7142–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Sagiv-Barfi I, Kohrt HE, Burckhardt L, Czerwinski DK, Levy R. Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in syngeneic mouse lymphoma model. Blood. 2015;125:2079–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Alizadeh AA, Brody J, et al. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood. 2011;117:2423–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Kohrt HE, Thielens A, Marabelle A, Sagiv-Barfi I, Sola C, Chanuc F, et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood. 2014;123:678–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 2010;142:699–713.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Département d’Innovation Thérapeutique et d’Essais Précoces, Gustave Roussy, Université Paris-Saclay, 114, rue Édouard-Vaillant, 94805, Villejuif, Cedex, France

    Aurélien Marabelle MD, PhD

  2. Gustave Roussy, INSERM U1015, Villejuif, 94805, France

    Aurélien Marabelle MD, PhD

Authors
  1. Aurélien Marabelle MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aurélien Marabelle MD, PhD .

Editor information

Editors and Affiliations

  1. Gustave Roussy Cancer Center , Villejuif Cedex, France

    Laurence Zitvogel

  2. Gustave Roussy Cancer Center , Villejuif Cedex, France

    Guido Kroemer

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Marabelle, A. (2018). Tumor-Targeted Antibodies. In: Zitvogel, L., Kroemer, G. (eds) Oncoimmunology. Springer, Cham. https://doi.org/10.1007/978-3-319-62431-0_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-62431-0_18

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-62430-3

  • Online ISBN: 978-3-319-62431-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation